NW Bio Offers 'Promising Survival Data' in 51 GBM Patients Treated with DCVAX-L: Data Demonstrated Substantially Longer-Than-Expected Survival
March 27, 2015 at 09:02 AM EDT
Northwest Biotherapeutics, Inc. (NASDAQ: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for ...